Infectious Disease

Moderna applies for EUA for COVID-19 vaccine for use in adolescents

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

Moderna announced that it has applied for emergency approval from the FDA for its COVID-19 vaccine for use in adolescents ages 12-17.

If approved, it would be the second COVID-19 vaccine available for children in the United States after Pfizer BioNTech vaccination, which received an Emergency Authorization (EUA) for children 12 years and older last month.

Source: Adobe Stock.

Source: Adobe Stock.

Moderna’s application is based on the results of a phase 2/3 study that showed the vaccine was as effective in adolescents as it was in adults.

“We are encouraged that the Moderna COVID-19 vaccine has been highly effective in preventing COVID-19 and SARS-CoV-2 infections in adolescents. We remain determined to help end the COVID-19 pandemic, ”said Moderna CEO Stephane Bancel said in a statement.

It took the FDA 31 days to approve the Pfizer BioNTech adolescent vaccine after the companies formally applied for the expanded EEA.

The Biden administration is seeking to achieve a goal of at least partially vaccinating 70% of eligible Americans by July 4th. An essential part of the plan is to vaccinate children.

As of June 1st, 3,994,151 pediatric COVID-19 cases were reported in the United States, accounting for 14.1% of all COVID-19 cases in the country.

References:

AAP. Children and COVID-19: Country Level Data Report. https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. Accessed June 10, 2021.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles